Valuation : Lupin Limited

Market Cap 949B 9.92B 8.53B 8.05B 7.34B 13.71B 13.84B 95.9B 36.91B 481B 37.26B 36.45B 1,529B P/E 2027 *
21.6x
P/E 2028 * 20.2x
Enterprise Value 908B 9.5B 8.17B 7.71B 7.02B 13.12B 13.24B 91.78B 35.33B 461B 35.67B 34.89B 1,463B EV / Sales 2027 *
3x
EV / Sales 2028 * 2.7x
Free-Float
52.98%
Yield 2027 *
0.62%
Yield 2028 * 0.62%
1 day-0.81%
1 week-3.60%
Current month-4.73%
1 month-12.08%
3 months-8.32%
6 months-9.85%
Current year-1.75%
1 week 2,060.55
Extreme 2060.55
2,149.75
1 month 2,060.55
Extreme 2060.55
2,307.55
Current year 2,060.55
Extreme 2060.55
2,530
1 year 1,900.3
Extreme 1900.3
2,530
3 years 1,091.8
Extreme 1091.8
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 01/09/2013
Director of Finance/CFO 61 13/08/2007
Compliance Officer - 01/09/2024
Director TitleAgeSince
Director/Board Member 52 08/10/2008
Director/Board Member 58 01/01/1997
Chairman 83 11/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-3.60%+5.92%+83.84% 10.05B
+0.03%-3.05%+48.98%+88.77% 1,002B
-0.18%-4.17%+51.79%+64.04% 644B
+1.06%-2.51%+19.87%+70.22% 443B
-0.63%-3.09%+29.84%+36.08% 343B
+0.43%-14.61%+11.32%+26.98% 262B
+0.93%-3.19%-1.31%+11.96% 245B
-2.15%-13.79%+37.48%+46.30% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-0.63%-4.32%+25.54%+87.81% 181B
Average -0.14%-4.78%+21.10%+45.79% 353.97B
Weighted average by Cap. +0.04%-4.24%+31.93%+56.11%

Financials

2027 *2028 *
Net sales 303B 3.17B 2.72B 2.57B 2.34B 4.38B 4.42B 30.62B 11.78B 154B 11.9B 11.64B 488B 323B 3.38B 2.9B 2.74B 2.5B 4.67B 4.71B 32.64B 12.56B 164B 12.68B 12.41B 520B
Net income 44.04B 461M 396M 374M 341M 637M 642M 4.45B 1.71B 22.34B 1.73B 1.69B 70.95B 46.93B 491M 422M 398M 363M 678M 684M 4.74B 1.83B 23.8B 1.84B 1.8B 75.61B
Net Debt -40.7B -426M -366M -345M -315M -588M -594M -4.11B -1.58B -20.64B -1.6B -1.56B -65.57B -75.52B -790M -679M -641M -584M -1.09B -1.1B -7.63B -2.94B -38.31B -2.97B -2.9B -122B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
10/09/26 2,075.00 -0.81% 135,054
09/09/26 ₹2,092.00 -0.95% 42,250
08/09/26 ₹2,112.00 +0.33% 47,143
07/09/26 ₹2,105.00 -0.28% 158,042
04/09/26 ₹2,111.00 -1.12% 19,665
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
2,075.00INR
Average target price
2,490.58INR
Spread / Average Target
+20.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!